Iris Completes Purchase of AlliedPath for Up to $6M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Iris International said today it has completed its acquisition of AlliedPath for up to $6 million.

The deal was originally announced last week and includes $4.7 million in cash to AlliedPath and up to $1.3 million in an earn-out, subject to certain sales and earnings targets being met over the next three years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.